Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | $0.0 | $0.0 | $0.0 | $20.1M | $30.9M | $231.0K | $28.6M | $27.4M | $26.6M | $60.0M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Protagonist Therapeutics, Inc.'s last 12-month Revenue is $323.8M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Protagonist Therapeutics, Inc.'s Revenue growth was N/A. The average annual Revenue growth rates for Protagonist Therapeutics, Inc. have been 118.2% over the past three years, N/A over the past five years.